Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most tuberculosis-related deaths in people with HIV could be prevented with earlier diagnosis and treatment. The only commercially available tuberculosis point-of-care test (Alere Determine TB LAM Ag [AlereLAM]) has suboptimal sensitivity, which restricts its use in clinical practice. The novel Fujifilm SILVAMP TB LAM (FujiLAM) assay has been developed to improve the sensitivity of AlereLAM. We assessed the diagnostic accuracy of the FujiLAM assay for the detection of tuberculosis in hospital inpatients with HIV compared with the AlereLAM assay. METHODS: For this diagnostic accuracy study, we assessed biobanked urine samples obtained from the FIND Specimen Bank and the University of Cape Town Biobank, which had been collected from hospital inpatients (aged ≥18 years) with HIV during three independent prospective cohort studies done at two South African hospitals. Urine samples were tested using FujiLAM and AlereLAM assays. The conduct and reporting of each test was done blind to other test results. The primary objective was to assess the diagnostic accuracy of FujiLAM compared with AlereLAM, against microbiological and composite reference standards (including clinical diagnoses). FINDINGS: Between April 18, 2018, and May 3, 2018, urine samples from 968 hospital inpatients with HIV were evaluated. The prevalence of microbiologically-confirmed tuberculosis was 62% and the median CD4 count was 86 cells per μL. Using the microbiological reference standard, the estimated sensitivity of FujiLAM was 70·4% (95% CI 53·0 to 83·1) compared with 42·3% (31·7 to 51·8) for AlereLAM (difference 28·1%) and the estimated specificity of FujiLAM was 90·8% (86·0 to 94·4) and 95·0% (87·7-98·8) for AlereLAM (difference -4·2%). Against the composite reference standard, the specificity of both assays was higher (95·7% [92·0 to 98·0] for FujiLAM vs 98·2% [95·7 to 99·6] for AlereLAM; difference -2·5%), but the sensitivity of both assays was lower (64·9% [50·1 to 76·7] for FujiLAM vs 38·2% [28·1 to 47·3] for AlereLAM; difference 26·7%). INTERPRETATION: In comparison to AlereLAM, FujiLAM offers superior diagnostic sensitivity, while maintaining specificity, and could transform rapid point-of-care tuberculosis diagnosis for hospital inpatients with HIV. The applicability of FujiLAM for settings of intended use requires prospective assessment. FUNDING: Global Health Innovative Technology Fund, UK Department for International Development, Dutch Ministry of Foreign Affairs, Bill & Melinda Gates Foundation, German Federal Ministry of Education and Research, Australian Department of Foreign Affairs and Trade, Wellcome Trust, Department of Science and Technology and National Research Foundation of South Africa, and South African Medical Research Council.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit
Cohen, J. (1968) · Psychological Bulletin · doi:10.1037/h0026256 · Cited by 8,736
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Self-citationTHE COMPARISON OF PERCENTAGES IN MATCHED SAMPLES
COCHRAN, W. G. (1950) · Biometrika · doi:10.1093/biomet/37.3-4.256 · Cited by 1,465
STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.246280 · Cited by 984
Gupta-Wright, A., Corbett, E. L., van Oosterhout, J. J., Wilson, D., Grint, D., Alufandika-Moyo, M., Peters, J. A., Chiume, L., Flach, C., Lawn, S. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31267-4 · Cited by 213
Cited by
Bjerrum, S., Schiller, I., Dendukuri, N., Kohli, M., Nathavitharana, R. R., Zwerling, A. A., Denkinger, C. M., Steingart, K. R., & Shah, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011420.pub3 · Cited by 186
“Of note, in 2018, preliminary performance characteristics of a second commercially developed lateral flow assay to detect LAM for the diagnosis of tuberculosis was announced based on data from frozen biobank specimens (Fujifilm SILVAMP TB LAM, Japan; FujiLAM) (Broger 2019).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Broger, T., Sossen, B., du Toit, E., Kerkhoff, A. D., Schutz, C., Ivanova Reipold, E., Ward, A., Barr, D. A., Macé, A., Trollip, A., Burton, R., Ongarello, S., Pinter, A., Lowary, T. L., Boehme, C., Nicol, M. P., Meintjes, G., & Denkinger, C. M.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 19
- Issue
- 8
- Pages
- 852-861
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2947213077
- Cited by
- 218
- References
- 5
- FWCI
- 22.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. https://app.cochat.ai/papers/10.1016/s1473-3099(19)30001-5
- The paper
- Broger, T., Sossen, B., du Toit, E., Kerkhoff, A. D., Schutz, C., Ivanova Reipold, E., Ward, A., Barr, D. A., Macé, A., Trollip, A., Burton, R., Ongarello, S., Pinter, A., Lowary, T. L., Boehme, C., Nicol, M. P., Meintjes, G., & Denkinger, C. M. (2019). Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(19)30001-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.